NZ258412A
(en)
*
|
1992-12-11 |
1997-01-29 |
Merck & Co Inc |
Spiro-fused piperidine derivatives and pharmaceutical compositions
|
US5492920A
(en)
*
|
1993-12-10 |
1996-02-20 |
Merck & Co., Inc. |
Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone
|
US5492916A
(en)
*
|
1993-12-23 |
1996-02-20 |
Merck & Co., Inc. |
Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
|
US5494919A
(en)
*
|
1993-11-09 |
1996-02-27 |
Merck & Co., Inc. |
2-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
|
WO1995014666A1
(en)
*
|
1993-11-24 |
1995-06-01 |
Merck & Co., Inc. |
Indolyl group containing compounds and the use thereof to promote the release of growth hormone(s)
|
US5721251A
(en)
*
|
1993-12-10 |
1998-02-24 |
Merck & Co., Inc. |
Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone
|
US5721250A
(en)
*
|
1993-12-23 |
1998-02-24 |
Merck & Co. Inc. |
Di-and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
|
AU3128195A
(en)
*
|
1994-07-20 |
1996-02-16 |
Merck & Co., Inc. |
Piperidines and hexahydro-1h-azepines spiro substituted at the 4-position promote release of growth hormone
|
US5656606A
(en)
*
|
1995-02-17 |
1997-08-12 |
Merck & Co., Inc. |
Camphor compounds promote release of growth hormone
|
US5731317A
(en)
*
|
1995-03-10 |
1998-03-24 |
Merck & Co., Inc. |
Bridged piperidines promote release of growth hormone
|
US5559128A
(en)
*
|
1995-04-18 |
1996-09-24 |
Merck & Co., Inc. |
3-substituted piperidines promote release of growth hormone
|
US5616571A
(en)
*
|
1995-06-06 |
1997-04-01 |
Merck & Co., Inc. |
Bisphosphonates prevent bone loss associated with immunosuppressive therapy
|
WO1997011697A1
(en)
*
|
1995-09-26 |
1997-04-03 |
Merck & Co., Inc. |
3-spirolactam, 3-spiroamino, 3-spirolactone and 3-spirobenzopyran piperidines and pyrrolidines promote release of growth hormone
|
US6028196A
(en)
*
|
1995-10-27 |
2000-02-22 |
Merck & Co., Inc. |
Process for the preparation of a growth hormone secretagogue
|
EA199800337A1
(ru)
*
|
1995-10-27 |
1998-10-29 |
Мерк Энд Ко., Инк. |
Способ получения гормона роста, усиливающего секрецию
|
US5767124A
(en)
*
|
1995-10-27 |
1998-06-16 |
Merck & Co., Inc. |
Polymorphic forms of a growth hormone secretagogue
|
CA2234817A1
(en)
*
|
1995-10-27 |
1997-05-01 |
Mandana Asgharnejad |
Wet granulation formulation of a growth hormone secretagogue
|
US6531314B1
(en)
|
1996-12-10 |
2003-03-11 |
Merck & Co., Inc. |
Growth hormone secretagogue receptor family
|
WO1997022004A1
(en)
|
1995-12-13 |
1997-06-19 |
Merck & Co., Inc. |
Assays for growth hormone secretagogue receptors
|
GB2308362A
(en)
*
|
1995-12-19 |
1997-06-25 |
Lilly Industries Ltd |
Pharmaceutical indole derivatives
|
WO1997022367A1
(en)
*
|
1995-12-20 |
1997-06-26 |
Merck & Co., Inc. |
Radiolabeled growth hormone secretagogue
|
GB9601724D0
(en)
*
|
1996-01-29 |
1996-03-27 |
Merck Sharp & Dohme |
Therapeutic agents
|
HN1996000101A
(es)
|
1996-02-28 |
1997-06-26 |
Inc Pfizer |
Terapia combinada para la osteoporosis
|
WO1997034604A1
(en)
*
|
1996-03-21 |
1997-09-25 |
Merck & Co., Inc. |
4-spiroindoline piperidines promote release of growth hormone
|
GB9612276D0
(en)
*
|
1996-06-12 |
1996-08-14 |
Merck & Co Inc |
4-Spiroindoline piperidines promote release of growth hormone
|
US5804578A
(en)
*
|
1996-04-03 |
1998-09-08 |
Merck & Co., Inc. |
Piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
|
EP0900086A4
(en)
*
|
1996-05-07 |
2000-01-12 |
Merck & Co Inc |
IMPROVING THE SLEEP BY MEANS OF A SUBSTANCE PROMOTING THE SECRETION OF GROWTH HORMONES
|
AU2931997A
(en)
*
|
1996-05-07 |
1997-11-26 |
Merck & Co., Inc. |
Treatment of mood disorders with a growth hormone secretagogue
|
US5877182A
(en)
*
|
1996-09-13 |
1999-03-02 |
Merck & Co., Inc. |
Piperidines promote release of growth hormone
|
AU4342097A
(en)
*
|
1996-09-13 |
1998-04-02 |
Merck & Co., Inc. |
Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
|
US6046333A
(en)
*
|
1996-10-25 |
2000-04-04 |
Merck & Co., Inc. |
Convergent process for the preparation of a growth hormone secretagogue
|
WO1998019699A1
(en)
*
|
1996-11-05 |
1998-05-14 |
Novo Nordisk A/S |
Use of growth hormone or a growth hormone secretagogue for promoting bone formation
|
AU5594398A
(en)
*
|
1996-12-09 |
1998-07-03 |
Merck & Co., Inc. |
Methods and compositions for preventing and treating bone loss
|
WO1998025605A1
(en)
*
|
1996-12-13 |
1998-06-18 |
Merck & Co., Inc. |
Spiro-substituted azacycles as modulators of chemokine receptor activity
|
US5962462A
(en)
*
|
1996-12-13 |
1999-10-05 |
Merck & Co., Inc. |
Spiro-substituted azacycles as modulators of chemokine receptor activity
|
UA59384C2
(uk)
|
1996-12-20 |
2003-09-15 |
Пфайзер, Інк. |
Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
|
AU7105498A
(en)
*
|
1997-04-14 |
1998-11-11 |
Merck & Co., Inc. |
Combination therapy for the prevention and treatment of osteoporosis
|
GB2324726A
(en)
*
|
1997-05-01 |
1998-11-04 |
Merck & Co Inc |
Combination Therapy for the Treatment of Osteoporosis
|
US6329342B1
(en)
|
1997-08-19 |
2001-12-11 |
Eli Lilly And Company |
Treatment of congestive heart failure with growth hormone secretagogues
|
US6374762B1
(en)
*
|
1997-10-27 |
2002-04-23 |
Correct Craft, Inc. |
Water sport towing apparatus
|
US6117880A
(en)
*
|
1997-10-30 |
2000-09-12 |
Merck & Co., Inc. |
Somatostatin agonists
|
US6013652A
(en)
*
|
1997-12-04 |
2000-01-11 |
Merck & Co., Inc. |
Spiro-substituted azacycles as neurokinin antagonists
|
DE69921611T2
(de)
|
1998-01-16 |
2005-11-03 |
Novo Nordisk A/S |
Verbindungen mit wachstumshormon-freisetzenden eigenschaften
|
JP2002517444A
(ja)
*
|
1998-06-11 |
2002-06-18 |
メルク エンド カムパニー インコーポレーテッド |
メラノコルチン受容体作動薬としてのスピロピペリジン誘導体
|
US6294534B1
(en)
|
1998-06-11 |
2001-09-25 |
Merck & Co., Inc. |
Spiropiperidine derivatives as melanocortin receptor agonists
|
US6682908B1
(en)
|
1998-07-10 |
2004-01-27 |
Merck & Co., Inc. |
Mouse growth hormone secretagogue receptor
|
WO2000002919A1
(en)
|
1998-07-13 |
2000-01-20 |
Merck & Co., Inc. |
Growth hormone secretagogue related receptors and nucleic acids
|
CA2340095A1
(en)
|
1998-08-10 |
2000-02-24 |
Merck & Co., Inc. |
Canine growth hormone secretagogue receptor
|
US6639076B1
(en)
|
1998-08-18 |
2003-10-28 |
Eli Lilly And Company |
Growth hormone secretagogues
|
US6194402B1
(en)
|
1998-09-02 |
2001-02-27 |
Merck & Co., Inc. |
Enhancement of return to independent living status with a growth hormone secretagogue
|
US6380184B1
(en)
|
1998-10-28 |
2002-04-30 |
Bristol-Myers Squibb Co. |
Benzoazepines and analogs thereof useful as growth hormone secretagogues
|
CA2362290A1
(en)
|
1999-02-18 |
2000-08-24 |
Kaken Pharmaceutical Co., Ltd. |
Novel amide derivatives as growth hormone secretagogues
|
US6828331B1
(en)
*
|
1999-02-19 |
2004-12-07 |
Eli Lilly And Company |
Growth hormone secretagogues
|
US6541634B2
(en)
|
1999-02-26 |
2003-04-01 |
Pfizer Inc. |
Process for preparing growth hormone secretagogues
|
US6518292B1
(en)
*
|
1999-03-12 |
2003-02-11 |
Bristol-Myers Squibb Co. |
Heterocyclic aromatic compounds usefuls as growth hormone secretagogues
|
US6525203B1
(en)
|
1999-03-12 |
2003-02-25 |
Bristol-Myers Squibb Company |
Heterocyclic aromatic compounds useful as growth hormone secretagogues
|
AU766191B2
(en)
|
1999-06-04 |
2003-10-09 |
Merck & Co., Inc. |
Substituted piperidines as melanocortin-4 receptor agonists
|
US20040266802A1
(en)
*
|
1999-06-07 |
2004-12-30 |
Alain Calvet |
Tricyclic analgesics
|
US6420376B1
(en)
*
|
1999-07-13 |
2002-07-16 |
Merck & Co., Inc. |
Amido spiropiperidines promote the release of growth hormone
|
WO2001060796A1
(en)
*
|
2000-02-18 |
2001-08-23 |
Meiji Seika Kaisha, Ltd. |
PHENOXYALKYLAMINE DERIVATIVES USEFUL AS OPIOID δ RECEPTOR AGONISTS
|
AU2001249296B2
(en)
|
2000-03-23 |
2005-03-24 |
Merck Sharp & Dohme Corp. |
Substituted piperidines as melanocortin receptor agonists
|
CA2403631A1
(en)
|
2000-03-23 |
2001-09-27 |
Brenda L. Palucki |
Spiropiperidine derivatives as melanocortin receptor agonists
|
JP2004507456A
(ja)
|
2000-05-11 |
2004-03-11 |
ブリストル−マイヤーズ スクイブ カンパニー |
成長ホルモン分泌促進薬として有用なテトラヒドロイソキノリン類縁体
|
ES2333097T3
(es)
|
2000-05-31 |
2010-02-17 |
Raqualia Pharma Inc |
Uso de secretagogos de la hormona de crecimiento para estimular la motilidad gastrointestinal.
|
JP2004506687A
(ja)
|
2000-08-23 |
2004-03-04 |
メルク エンド カムパニー インコーポレーテッド |
メラノコルチン受容体作働薬としての置換ピペリジン類
|
AP1699A
(en)
*
|
2001-03-21 |
2006-12-26 |
Warner Lambert Co |
New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
|
WO2002085354A1
(en)
|
2001-04-18 |
2002-10-31 |
Euro-Celtique S.A. |
Spiroindene and spiroindane compounds
|
US6911447B2
(en)
*
|
2001-04-25 |
2005-06-28 |
The Procter & Gamble Company |
Melanocortin receptor ligands
|
WO2002094825A1
(fr)
*
|
2001-05-22 |
2002-11-28 |
Banyu Pharmaceutical Co., Ltd. |
Nouveau derive de spiropiperidine
|
US7125840B2
(en)
*
|
2001-10-09 |
2006-10-24 |
Eli Lilly And Company |
Substituted dipeptides as growth hormone secretagogues
|
US6649606B1
(en)
|
2001-11-09 |
2003-11-18 |
Bristol-Myers Squibb Co. |
Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
|
DE60306636T2
(de)
*
|
2002-04-09 |
2007-07-05 |
Eli Lilly And Co., Indianapolis |
Wachstumhormonsekretionsförderer
|
US20060167268A1
(en)
*
|
2002-04-09 |
2006-07-27 |
Eli Lilly And Company, Patent Division, |
Growth hormone secretagogues
|
US7026335B2
(en)
|
2002-04-30 |
2006-04-11 |
The Procter & Gamble Co. |
Melanocortin receptor ligands
|
US20040010010A1
(en)
*
|
2002-04-30 |
2004-01-15 |
Ebetino Frank Hallock |
Melanocortin receptor ligands
|
GB0213715D0
(en)
*
|
2002-06-14 |
2002-07-24 |
Syngenta Ltd |
Chemical compounds
|
TW200504033A
(en)
*
|
2002-10-23 |
2005-02-01 |
Procter & Gamble |
Melanocortin receptor ligands
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
CN1297557C
(zh)
*
|
2003-04-10 |
2007-01-31 |
上海药明康德新药开发有限公司 |
螺环类模板化合物的制备
|
US7476653B2
(en)
|
2003-06-18 |
2009-01-13 |
Tranzyme Pharma, Inc. |
Macrocyclic modulators of the ghrelin receptor
|
WO2005027913A1
(en)
*
|
2003-09-19 |
2005-03-31 |
Pfizer Products Inc. |
Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue
|
US20070123470A1
(en)
*
|
2003-10-24 |
2007-05-31 |
Wladimir Hogenhuis |
Enhancement of growth hormone levels with a dipeptidyl peptidase IV inhibitor and a growth hormone secretagogue
|
CA2544602A1
(en)
|
2003-11-04 |
2005-05-26 |
Elixir Pharmaceuticals, Inc. |
Therapeutic compounds and uses thereof
|
GB0328906D0
(en)
*
|
2003-12-12 |
2004-01-14 |
Syngenta Participations Ag |
Chemical compounds
|
GB0328908D0
(en)
*
|
2003-12-12 |
2004-01-14 |
Syngenta Participations Ag |
Chemical compounds
|
JP2007531739A
(ja)
*
|
2004-04-02 |
2007-11-08 |
エリクシアー ファーマシューティカルズ, インコーポレイテッド |
スルホンアミドおよびそれらの使用
|
UA87854C2
(en)
|
2004-06-07 |
2009-08-25 |
Мерк Энд Ко., Инк. |
N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
|
AU2005277389A1
(en)
|
2004-08-18 |
2006-03-02 |
Elixir Pharmaceuticals, Inc. |
Growth-hormone secretagogues
|
US7786141B2
(en)
*
|
2004-08-19 |
2010-08-31 |
Vertex Pharmaceuticals Incorporated |
Dihydrospiroindene modulators of muscarinic receptors
|
MX2007002033A
(es)
*
|
2004-08-19 |
2007-04-26 |
Vertex Pharma |
Moduladores de receptores muscarinicos.
|
CA2581415C
(en)
*
|
2004-10-28 |
2011-10-04 |
Sankyo Company Limited |
Optically active 4,4-di-substituted oxazolidine derivatives and procedures for their preparation
|
AU2005309365B2
(en)
*
|
2004-11-29 |
2011-10-06 |
Vertex Pharmaceuticals Incorporated |
Modulators of muscarinic receptors
|
KR20080048502A
(ko)
|
2005-09-29 |
2008-06-02 |
머크 앤드 캄파니 인코포레이티드 |
멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
|
EP1973543A2
(en)
*
|
2005-12-22 |
2008-10-01 |
Vertex Pharmaceuticals Incorporated |
Modulators of muscarinic receptors
|
AU2007221214A1
(en)
|
2006-02-22 |
2007-09-07 |
Vertex Pharmaceuticals Incorporated |
Modulators of muscarinic receptors
|
RU2008137583A
(ru)
*
|
2006-02-22 |
2010-03-27 |
Вертекс Фармасьютикалз Инкорпорейшн (Us) |
Спиропиперидины в качестве модуляторов мускариновых рецепторов
|
CU23558A1
(es)
|
2006-02-28 |
2010-07-20 |
Ct Ingenieria Genetica Biotech |
Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
|
CN101092396B
(zh)
*
|
2006-06-20 |
2010-09-15 |
上海药明康德新药开发有限公司 |
螺[1,3-二氢茚-4'-哌啶-1-羧酸]模板化合物的制备方法
|
CA2656183A1
(en)
*
|
2006-06-29 |
2008-01-10 |
Vertex Pharmaceuticals Incorporated |
Modulators of muscarinic receptors
|
CA2660903A1
(en)
*
|
2006-08-15 |
2008-02-21 |
Vertex Pharmaceuticals Incorporated |
Modulators of muscarinic receptors
|
JP2010501561A
(ja)
*
|
2006-08-18 |
2010-01-21 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
ムスカリン受容体の調節剤
|
CA2664113C
(en)
|
2006-09-22 |
2013-05-28 |
Merck & Co., Inc. |
Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
|
US8138197B2
(en)
*
|
2007-01-12 |
2012-03-20 |
Msd K.K. |
Spirochromanon derivatives
|
EP2644618B1
(en)
|
2007-02-09 |
2016-08-17 |
Ocera Therapeutics, Inc. |
tether intermediates for the synthesis of macrocyclic ghrelin receptor modulators
|
WO2008134828A2
(en)
|
2007-05-04 |
2008-11-13 |
Katholieke Universiteit Leuven |
Tissue degeneration protection
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
AU2008261102B2
(en)
|
2007-06-04 |
2013-11-28 |
Bausch Health Ireland Limited |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
JP2010540640A
(ja)
*
|
2007-10-03 |
2010-12-24 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
ムスカリン作用性レセプターのモジュレーター
|
WO2009061676A2
(en)
*
|
2007-11-06 |
2009-05-14 |
Amira Pharmaceuticals, Inc. |
Antagonists of pgd2 receptors
|
EP2328910B1
(en)
|
2008-06-04 |
2014-08-06 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
EP3241839B1
(en)
|
2008-07-16 |
2019-09-04 |
Bausch Health Ireland Limited |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
|
EA201170624A1
(ru)
|
2008-10-30 |
2011-12-30 |
Мерк Шарп Энд Домэ Корп. |
Изоникотинамидные антагонисты рецепторов орексинов
|
AU2011284801B2
(en)
*
|
2010-07-28 |
2016-01-28 |
The University Of Queensland |
Modulators of protease activated receptors
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
US8546416B2
(en)
*
|
2011-05-27 |
2013-10-01 |
Novartis Ag |
3-spirocyclic piperidine derivatives as ghrelin receptor agonists
|
AU2012286594B2
(en)
*
|
2011-07-28 |
2017-01-19 |
The University Of Queensland |
Modulators of protease activated receptors
|
AR088352A1
(es)
|
2011-10-19 |
2014-05-28 |
Merck Sharp & Dohme |
Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
|
WO2013190520A2
(en)
|
2012-06-22 |
2013-12-27 |
The General Hospital Corporation |
Gh-releasing agents in the treatment of vascular stenosis and associated conditions
|
JP6262661B2
(ja)
|
2012-10-24 |
2018-01-17 |
第一三共株式会社 |
筋萎縮性側索硬化症治療剤
|
AU2014235209B2
(en)
|
2013-03-15 |
2018-06-14 |
Bausch Health Ireland Limited |
Guanylate cyclase receptor agonists combined with other drugs
|
WO2014151206A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
BR112015030326A2
(pt)
|
2013-06-05 |
2017-08-29 |
Synergy Pharmaceuticals Inc |
Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
|
WO2015054500A2
(en)
|
2013-10-09 |
2015-04-16 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
|
US9119832B2
(en)
|
2014-02-05 |
2015-09-01 |
The Regents Of The University Of California |
Methods of treating mild brain injury
|
EP3134408B1
(en)
|
2014-04-22 |
2020-08-12 |
Merck Sharp & Dohme Corp. |
FACTOR XIa INHIBITORS
|
BR112016027778A2
(pt)
|
2014-05-30 |
2017-08-15 |
Pfizer |
Usos de derivados de carbonitrila, sua combinação e sua composição farmacêutica
|
WO2017075535A1
(en)
|
2015-10-28 |
2017-05-04 |
Oxeia Biopharmaceuticals, Inc. |
Methods of treating neurodegenerative conditions
|
AU2018291163B2
(en)
*
|
2017-06-30 |
2024-07-18 |
Quixgen, Inc. |
Novel spirolactone compounds
|
KR20200138714A
(ko)
|
2018-02-21 |
2020-12-10 |
에이아이 테라퓨틱스, 인코포레이티드 |
아필리모드 및 글루타메이트성 작용제를 사용한 병용 요법
|
US11098029B2
(en)
|
2019-02-13 |
2021-08-24 |
Merck Sharp & Dohme Corp. |
5-alkyl pyrrolidine orexin receptor agonists
|
EP4010314B1
(en)
|
2019-08-08 |
2024-02-28 |
Merck Sharp & Dohme LLC |
Heteroaryl pyrrolidine and piperidine orexin receptor agonists
|
MX2023001840A
(es)
|
2020-08-18 |
2023-03-13 |
Merck Sharp & Dohme Llc |
Agonistas de bicicloheptano pirrolidina de los receptores de orexina.
|
WO2023275715A1
(en)
|
2021-06-30 |
2023-01-05 |
Pfizer Inc. |
Metabolites of selective androgen receptor modulators
|